HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
We have evaluated HER2/neu expression in 1,355 breast cancer patients recruited at the Breast Cancer Registry in Palermo between January 1999 and December 2004. In this retrospective study, HER2/neu expression was related to clinicopathologic features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors. Statistical analysis on all 1,355 patients showed a significant correlation between HER2/neu and nodal status (P < 0.001), and a significant association between HER2/neu overexpression and estrogen and progesterone receptors status (P < 0.001). In 194 patients without metastasis, with an average follow-up > or =5 years, only HER2/neu 3+ and histopathologic grading G3 were significantly associated with overall survival.
Traina
Adele
A
Experimental Oncology, Department of Oncology, P.O. M. Ascoli, via Parlavecchio n. 139, 90127 Palermo, Italy. registrotumori@ospedalecivicopa.org
Agostara
Biagio
B
Marasà
Lorenzo
L
Calabrò
Maurizio
M
Zarcone
Maurizio
M
Carruba
Giuseppe
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D016019:Survival Analysis
D018719:Erb-b2 Receptor Tyrosine Kinases